A Phase 3 Multinational, Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Ph+ Chronic Phase Chronic Myeloid Leukemia Patients With Failure or Intolerance to Previous TKIs Therapy Including Imatinib
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Radotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Il-Yang
- 07 Mar 2019 Planned number of patients changed from 195 to 173.
- 31 Aug 2018 Biomarkers information updated
- 20 Jul 2018 Status changed from not yet recruiting to recruiting.